-
EP3079696
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3079696
| EP3079696 - ADENOSINE A1 AGONISTS AS MEDICAMENTS AGAINST RENAL DISEASES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 11.10.2019 Database last updated on 03.09.2024 | |
| Former | Examination is in progress Status updated on 18.01.2019 | Most recent event Tooltip | 11.10.2019 | Application deemed to be withdrawn | published on 13.11.2019 [2019/46] | Applicant(s) | For all designated states Bayer Pharma Aktiengesellschaft Müllerstrasse 178 13353 Berlin / DE | [2016/42] | Inventor(s) | 01 /
ALBRECHT-KÜPPER, Barbara Heidestr. 9 42489 Wülfrath / DE | 02 /
LEINEWEBER, Kirsten Laakmannsbusch 26 42555 Velbert-Langenberg / DE | 03 /
KRETSCHMER, Axel Am Acker 23 42113 Wuppertal / DE | 04 /
MEIBOM, Daniel In den Birken 62b 42113 Wuppertal / DE | 05 /
VAKALOPOULOS, Alexandros Heinrich-Heine-Str. 79a 40721 Hilden / DE | 06 /
DIEDRICHS, Nicole In der Heide 81 42553 Velbert / DE | 07 /
ZIMMERMANN, Katja Bockumer Str. 370 40489 Düsseldorf / DE | [2016/42] | Representative(s) | BIP Patents c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 50 40789 Monheim am Rhein / DE | [N/P] |
| Former [2016/42] | BIP Patents c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 10 40789 Monheim am Rhein / DE | Application number, filing date | 14809631.6 | 09.12.2014 | [2016/42] | WO2014EP76978 | Priority number, date | EP20130196780 | 12.12.2013 Original published format: EP 13196780 | [2016/42] | Filing language | DE | Procedural language | DE | Publication | Type: | A1 Application with search report | No.: | WO2015086561 | Date: | 18.06.2015 | Language: | DE | [2015/24] | Type: | A1 Application with search report | No.: | EP3079696 | Date: | 19.10.2016 | Language: | DE | The application published by WIPO in one of the EPO official languages on 18.06.2015 takes the place of the publication of the European patent application. | [2016/42] | Search report(s) | International search report - published on: | EP | 18.06.2015 | Classification | IPC: | A61K31/4439, A61P13/12 | [2016/42] | CPC: |
C07D417/12 (EP,US);
A61K31/4427 (KR);
A61K31/427 (KR);
A61K31/4439 (EP,KR,US);
A61P13/12 (EP);
A61P43/00 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/42] | Extension states | BA | 12.07.2016 | ME | 12.07.2016 | Title | German: | ADENOSIN A1 AGONISTEN ALS ARZNEIMITTEL GEGEN NIERENERKRANKUNGEN | [2016/42] | English: | ADENOSINE A1 AGONISTS AS MEDICAMENTS AGAINST RENAL DISEASES | [2016/42] | French: | AGONISTES A1 DE L'ADÉNOSINE UTILISÉS COMME MÉDICAMENTS CONTRE LES MALADIES DES REINS | [2016/42] | Entry into regional phase | 12.07.2016 | National basic fee paid | 12.07.2016 | Designation fee(s) paid | 12.07.2016 | Examination fee paid | Examination procedure | 12.07.2016 | Examination requested [2016/42] | 17.01.2017 | Amendment by applicant (claims and/or description) | 17.01.2019 | Despatch of a communication from the examining division (Time limit: M04) | 28.05.2019 | Application deemed to be withdrawn, date of legal effect [2019/46] | 03.07.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2019/46] | Fees paid | Renewal fee | 13.12.2016 | Renewal fee patent year 03 | 12.12.2017 | Renewal fee patent year 04 | 12.12.2018 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]US2005227972 (ROSENTRETER ULRICH [DE], et al) [A] 1-8 * paragraph [0009] - paragraph [0010] * * paragraph [0043] *; | [XI]DE102007036075 (BAYER HEALTHCARE AG [DE]) [X] 1-5,8 * example 2 * * paragraph [0004] * * paragraph [0041] * * paragraph [0007] * * paragraph [0044] * * paragraph [0042] - paragraph [0043] * [I] 6,7; | [X]US2010197609 (VAKALOPOULOS ALEXANDROS [DE], et al) [X] 1-6,8 * paragraph [0186] - paragraph [0167] * * paragraph [0176] * * paragraph [0367]; example 6 * * page 58; example 30 *; | [X]US2011294718 (LERCHEN HANS-GEORG [DE], et al) [X] 1-5,8 * claim 1 * * paragraph [0042] * * paragraph [0330]; example 16 *; | [A] - H. N. SABBAH ET AL, "Chronic Therapy With a Partial Adenosine A1-Receptor Agonist Improves Left Ventricular Function and Remodeling in Dogs With Advanced Heart Failure", CIRCULATION: HEART FAILURE, (20130405), vol. 6, no. 3, doi:10.1161/CIRCHEARTFAILURE.112.000208, ISSN 1941-3289, pages 563 - 571, XP055162851 [A] 1-8 * abstract * DOI: http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.000208 | [A] - CHRISTA E MÃ 1/4 LLER ET AL, "Recent developments in adenosine receptor ligands and their potential as novel drugs", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - BIOMEMBRANES, ELSEVIER, AMSTERDAM, NL, vol. 1808, no. 5, doi:10.1016/J.BBAMEM.2010.12.017, ISSN 0005-2736, (20101215), pages 1290 - 1308, (20101223), XP028157805 [A] 1-8 * section 4.1.1; page 1302, column r * DOI: http://dx.doi.org/10.1016/j.bbamem.2010.12.017 | [A] - LORENZ BOTT-FLÜGEL ET AL, "Selective Attenuation of Norepinephrine Release and Stress-Induced Heart Rate Increase by Partial Adenosine A1 Agonism", PLOS ONE, (20110328), vol. 6, no. 3, doi:10.1371/journal.pone.0018048, page e18048, XP055162651 [A] 1-8 * abstract * * page 4, column l, paragraph l * * figure 3 * DOI: http://dx.doi.org/10.1371/journal.pone.0018048 | Examination | WO2010086101 |